Fri, 10 Apr 2026 10:25:05 +0100 https://www.buzzsprout.com/2570892 en-gb © 2026 JnJ The Obesity Podcast yes c6b99f4c-58f5-5538-a98f-87ca3ce3bdf0 Johnson and Johnson episodic false The JnJ The Obesity Podcast is a Johnson & Johnson podcast series featuring expert-led discussions on obesity, metabolic health, and clinical innovation. The podcast brings together healthcare professionals and thought leaders to explore evidence-based perspectives and real-world practice.

]]> Buzzsprout (https://www.buzzsprout.com) Johnson and Johnson https://storage.buzzsprout.com/vmmw6e94rwnatvnqe573vgb9d2nv?.jpg The Obesity Podcast Ep.2: Medications, Mechanisms & the “Gateway Effect” discussion of incretin-based medications | J&J MedTech Joined by Professor David Cummings (University of Washington, Seattle), Paulina and Marco explore the revolutionary impact of new incretin-based medications such as semaglutide and tirzepatide. Cummings explains their origins in metabolic surgery research, how GLP-1 and GIP mechanisms work, and why the field has shifted dramatically after decades of weak pharmacological options. He addresses surgeons’ fears that drugs might replace operations, reframing them as complementary tools that can expand patient access and even drive more people into treatment pathways (the “gateway effect”). The discussion highlights unanswered questions-timing of drug use around surgery, long-term cost-effectiveness, and tailoring medications to individuals-but concludes that surgery and medications together form a stronger, multidisciplinary strategy against obesity.

]]> Joined by Professor David Cummings (University of Washington, Seattle), Paulina and Marco explore the revolutionary impact of new incretin-based medications such as semaglutide and tirzepatide. Cummings explains their origins in metabolic surgery research, how GLP-1 and GIP mechanisms work, and why the field has shifted dramatically after decades of weak pharmacological options. He addresses surgeons’ fears that drugs might replace operations, reframing them as complementary tools that can expand patient access and even drive more people into treatment pathways (the “gateway effect”). The discussion highlights unanswered questions-timing of drug use around surgery, long-term cost-effectiveness, and tailoring medications to individuals-but concludes that surgery and medications together form a stronger, multidisciplinary strategy against obesity.

]]> Johnson and Johnson Buzzsprout-18987877 Thu, 09 Apr 2026 11:00:00 +0100 2222 1 2 full false The Obesity Podcast Ep.1: Decoding a chronic disease | J&J MedTech Hosts Professor Paulina Salminen (Finland) and Professor Marco Bueter (Switzerland) introduce the new Obesity Podcast, setting the stage for open, stigma-free discussions around obesity as a chronic disease. They share personal backgrounds as bariatric surgeons and researchers, reflecting on their work in metabolic surgery, clinical trials, and eating-behavior research. Both emphasize that the podcast is not about promoting surgery but about offering an evidence-driven platform to discuss all treatment options, highlight current projects, and fight stigma around patients and therapies. The episode outlines their vision: data-driven dialogue, expert guests, and contributing to global understanding of obesity care.

]]> Hosts Professor Paulina Salminen (Finland) and Professor Marco Bueter (Switzerland) introduce the new Obesity Podcast, setting the stage for open, stigma-free discussions around obesity as a chronic disease. They share personal backgrounds as bariatric surgeons and researchers, reflecting on their work in metabolic surgery, clinical trials, and eating-behavior research. Both emphasize that the podcast is not about promoting surgery but about offering an evidence-driven platform to discuss all treatment options, highlight current projects, and fight stigma around patients and therapies. The episode outlines their vision: data-driven dialogue, expert guests, and contributing to global understanding of obesity care.

]]> Johnson and Johnson Buzzsprout-18983209 Thu, 09 Apr 2026 10:00:00 +0100 760 1 1 full false